Why Acyclovir Resistance Develops
Acyclovir resistance occurs mainly in herpes simplex virus (HSV) or varicella-zoster virus (VZV) when the virus mutates its thymidine kinase gene or alters viral DNA polymerase, reducing drug activation or binding. This is most common in immunocompromised patients (e.g., HIV, transplant recipients) on long-term or high-dose therapy, with rates up to 5-10% in such groups versus under 1% in immunocompetent individuals.[1][2]
Preventive Strategies in Clinical Practice
- Shorten treatment duration: Use the lowest effective dose and duration (e.g., 5-7 days for acute HSV episodes) to minimize selection pressure.
- Reserve for confirmed need: Test for active infection via PCR or culture before starting; avoid empiric use in low-risk cases.
- Monitor immunocompromised patients: Regular viral susceptibility testing (genotypic or phenotypic) if therapy exceeds 1-2 weeks; switch to alternatives like foscarnet if resistance emerges.
- Adhere to dosing: Follow guidelines—e.g., 400mg oral 3x/day for HSV suppression—to maintain levels above inhibitory concentrations.[3]
Patient Actions to Reduce Risk
- Take full courses as prescribed; partial adherence promotes mutants.
- Avoid self-medicating or sharing prescriptions, as suboptimal dosing fosters resistance.
- Manage underlying conditions (e.g., optimize HIV viral load) to lower viral replication burden.
When to Switch Therapies
Resistance is rare in primary outbreaks but rises with prophylaxis. Alternatives include:
| Drug | Use Case | Notes |
|------|----------|-------|
| Valacyclovir | Equivalent efficacy, better bioavailability | Prodrug of acyclovir; similar resistance profile [4] |
| Famciclovir | HSV/VZV alternative | Penciclovir prodrug; cross-resistance possible |
| Foscarnet | Resistant strains | IV only; nephrotoxic, for severe cases |
| Cidofovir | Second-line | Also nephrotoxic; topical for mucocutaneous HSV |
No vaccines prevent resistance directly, but HSV vaccines in trials may reduce overall viral load.
Testing for Resistance
Suspect if lesions persist/worsen after 7-10 days of therapy. Confirm via plaque reduction assay or sequencing (TK gene mutations like deletions most common).[5] Early detection prevents spread in outbreaks.
[1] CDC Guidelines on HSV Management
[2] Clinical Infectious Diseases Review on Antiviral Resistance
[3] IDSA HSV Guidelines
[4] Valacyclovir vs Acyclovir Meta-Analysis
[5] WHO Antiviral Resistance Surveillance